Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

Β-Catenin/lef1 Transactivates the Microrna-371-373 Cluster That Modulates the Wnt/β-catenin-signaling Pathway

The Wnt/β-Catenin/LEF1 Pathway Promotes Cell Proliferation at Least in Part Through Direct Upregulation of Mir-17-92 Cluster.

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

Mir-373-3p Targets DKK1 to Promote EMT-Induced Metastasis Via the Wnt/β-Catenin Pathway in Tongue Squamous Cell Carcinoma.

Aberrantly Expressed Mir-582-3p Maintains Lung Cancer Stem Cell-Like Traits by Activating Wnt/β-catenin Signalling

Wnt/β-catenin Pathway Represses Let-7 Micrornas Expression Via Transactivation of Lin28 to Augment Breast Cancer Stem Cell Expansion

Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways

Microrna-200a Suppresses The Wnt/Beta-Catenin Signaling Pathway By Interacting With Beta-Catenin

Wnt/β-catenin Pathway Transactivates Microrna-150 That Promotes EMT of Colorectal Cancer Cells by Suppressing CREB Signaling

MicroRNAs target the Wnt/-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer

Downregulation Of Mir-200a Induces Emt Phenotypes And Csc-Like Signatures Through Targeting The Beta-Catenin Pathway In Hepatic Oval Cells

Mir-942 Promotes Cancer Stem Cell-Like Traits In Esophageal Squamous Cell Carcinoma Through Activation Of Wnt/Beta-Catenin Signalling Pathway

MicroRNAs target the Wnt/β-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer

Upregulation of Long Intergenic Non-Coding RNA LINC00326 Inhibits Non-Small Cell Lung Carcinoma Progression by Blocking Wnt/β-catenin Pathway Through Modulating the Mir-657/Dickkopf WNT Signaling Pathway Inhibitor 2 Axis

miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.

MicroRNA-374a Activates Wnt/β-catenin Signaling to Promote Breast Cancer Metastasis.

Downregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the β-catenin pathway in hepatic oval cells.

Interference with the β-catenin gene in gastric cancer induces changes to the miRNA expression profile

MiR-4524b-5p/WTX/β-catenin Axis Functions As a Regulator of Metastasis in Cervical Cancer

Aflatoxin B1 Negatively Regulates Wnt/β-Catenin Signaling Pathway Through Activating Mir-33A

Regulation of Β-Catenin-mediated Esophageal Cancer Growth and Invasion by Mir-214.